Placeholder Banner

Adopting foreign price controls “prevents investors from being able to invest, and inventors from being able to invent.”

February 3, 2020
Media Contact
Author-Profile-Andrew-Segerman

In a new video, Alex Karnal, a life science investor and partner at Deerfield Management, shares why investing in new cures and treatments is personal, and he explains how President Trump’s plan to import foreign price controls would have an “absolutely chilling” effect on investments in transformational, life-saving therapies. 

 

“President Trump, we have got to lower drug prices at the pharmacy counter right now. In order to do that, we need four key groups to come together … and derive a holistic solution to treat the disease versus using foreign reference pricing as a scheme to focus on a single symptom.”

To learn more about the flaws of importing foreign price controls, visit bio.org/save-cures.

Additional resources:

###

Discover More
Washington, DC (December 2, 2020) - Dr. Michelle McMurry-Heath, President and CEO of the Biotechnology Innovation Organization (BIO), issued the following statement regarding Nasdaq's filing with the Securities and Exchange Commission…
Washington, DC (November 20, 2020) – Dr. Michelle McMurry-Heath, president and CEO of the Biotechnology Innovation Organization (BIO), issued the following statement after the Trump administration moved forward with its threat to impose…
"What a historic election for our country! For the first time in 120 years, American voter participation shattered many turnout records.    "At BIO we undertook an effort to mobilize and activate voters in our industry with Biotech Votes…